Pancreatic Cancer Research

ResearcherTheodor Bilharz Research InstituteActive in the last 2 years

Sara Maher

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9343-6617; OpenAlex author ID A5056981806. Sources: ClinicalTrials.gov.

Their work

Papers
2 (first author 1, last author 0)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
4
Papers, trials and grants by year

2021: 1 trial · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 2

  1. Assessing the diagnostic potential of SATB2 and β-catenin as biomarkers and therapeutic targets in pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00432-024-06055-z↗
  2. Synergistic immunomodulatory effect of synbiotics pre- and postoperative resection of pancreatic ductal adenocarcinoma: a randomized controlled study. Co-author DOI 10.1007/s00262-024-03686-6↗

Trials 1

  1. Synergistic Immunomodulatory Effect of Synbiotics Pre and Postoperative Resection of Pancreatic Ductal Adenocarcinoma Principal investigator NCT06199752↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Noha Said Helal · 2 shared papers, 2024–2025 · strength 0.51
  2. Mona Moussa · 1 shared paper, 2025 · strength 0.28
  3. Safia Samir · 1 shared paper, 2025 · strength 0.28
  4. Manal M. Kamel · 1 shared paper, 2024 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.